E637

E637

SCHEMBL290806

CCc1occc(=O)c1O.Cc1occc(=O)c1O

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.72
KDM4E B2RXH2 2/20 0.72
ALOX5 P09917 2/20 0.43
APP P05067 5/20 0.37
GAA P10253 1/20 0.36
MAPK1 P28482 1/20 0.35
KMT2A Q03164 1/20 0.34
HSD17B10 Q99714 1/20 0.33
TSHR P16473 1/20 0.33
ALDH1A1 P00352 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
CYP2C19 P33261 1/20 0.32
FTO Q9C0B1 1/20 0.32
GABRA1 P14867 1/20 0.31
GABRB2 P47870 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
E637 SCHEMBL11019418 0.98 LMNA (0.70) LMNAKDM4EALOX5APPGAA
E637 SCHEMBL1870685 0.91 KDM4E (0.55) LMNAKDM4EALOX5APPMAPK1
E637 SCHEMBL41817 0.91 KDM4E (0.55) LMNAKDM4EALOX5APPMAPK1
E637 SCHEMBL6657728 0.89 KDM4E (0.53) LMNAKDM4EALOX5APPMAPK1
E637 SCHEMBL27635951 0.89 KDM4E (0.53) LMNAKDM4EALOX5APPMAPK1
E637 SCHEMBL23309786 0.89 KDM4E (0.53) LMNAKDM4EALOX5APPMAPK1
E637 SCHEMBL8026696 0.89 KDM4E (0.53) LMNAKDM4EALOX5APPMAPK1
Maltol SCHEMBL4815 0.85
Maltol SCHEMBL901231 0.85 KDM4E (1.00) LMNAKDM4EALOX5APPGAA
E637 SCHEMBL14990891 0.84 KDM4E (0.48) LMNAKDM4EALOX5APPGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10260022-B2 Microcapsules imparting intense vanilla odor note FIRMENICH SA (CH) 2019-04-16 US disclosed
EP-3253455-B1 MICROCAPSULES IMPARTING INTENSE VANILLA ODOR NOTE FIRMENICH & CIE (CH) 2019-04-10 EP disclosed
US-20180023033-A1 MICROCAPSULES IMPARTING INTENSE VANILLA ODOR NOTE FIRMENICH SA (CH) 2018-01-25 US disclosed
WO-2016124746-A1 MICROCAPSULES IMPARTING INTENSE VANILLA ODOR NOTE FIRMENICH SA (CH) 2016-08-11 WO disclosed
US-20120082631-A1 COMPOSITIONS GIVAUDAN SA (CH) 2012-04-05 US disclosed
EP-2427248-A2 ZINC COMPRISING ORAL CARE COMPOSITIONS HAVING REDUCED ASTRINGENCY Givaudan SA (CH) 2012-03-14 EP disclosed
WO-2010128164-A2 COMPOSITIONS GIVAUDAN SA (CH) 2010-11-11 WO disclosed
CN-1048981-A Chrysanthemum products removes living green grass or young crops, pained abnormal smells from the patient method and prescription HUANG GUOGANG (CN) 1991-02-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10260022-B2 Microcapsules imparting intense vanilla odor note TRPC5, TRPV5, TRPM5 LMNA 4467/4885KDM4E 1690/4885ALOX5 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.